Association of CHFR promoter methylation with disease recurrence in locally advanced colon cancer

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Motofumi TanakaCathy Eng

Abstract

This study was designed to determine whether DNA methylation biomarkers are associated with recurrence and survival in colon cancer patients. A retrospective analysis of 82 patients who received curative surgical resection for American Joint Committee on Cancer (AJCC) high-risk stage II or III colon cancer (1999-2007) was conducted. DNA methylation status was quantitatively evaluated by the pyrosequencing method. We preselected three tumor suppressor genes and one locus of interest; CHFR, ID4, RECK, and MINT1. Mean methylation levels of multiple CpG sites in the promoter regions were used for analysis; 15% or more was defined as methylation positive. The association of recurrence-free survival (RFS) and overall survival (OS) with methylation status was analyzed by the log-rank test, Kaplan-Meier method, and Cox proportional hazards model. Methylation levels of ID4, MINT1, and RECK did not correlate with RFS or OS. CHFR was methylation positive in 63% patients. When methylation status was dichotomized (negative or low: <30%, high: ≥30%), patients with CHFR methylation-high (44%) had worse RFS (P = 0.006) and reduced OS (P = 0.069). When stratified by stage, CHFR methylation-high was associated with reduced RFS (P = 0.004) and OS...Continue Reading

References

Jan 13, 2000·The New England Journal of Medicine·R GryfeS Gallinger
Jan 19, 2000·Proceedings of the National Academy of Sciences of the United States of America·M ToyotaJ P Issa
Aug 10, 2000·Nature·D M Scolnick, T D Halazonetis
Jun 18, 2003·Proceedings of the National Academy of Sciences of the United States of America·Minoru ToyotaTakashi Tokino
Jul 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T E Le VoyerD G Haller
Jan 21, 2004·Nature Reviews. Cancer·Andrew P Feinberg, Benjamin Tycko
Jun 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Al B BensonDaniel G Haller
Dec 1, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Naoyuki UmetaniDave S B Hoon
Mar 29, 2005·Nature Genetics·Xiaochun YuJunjie Chen
Jul 1, 2005·The New England Journal of Medicine·Carmen Allegra, Daniel J Sargent
Oct 24, 2006·Cancer Treatment Reviews·Anna Maria ValentiniMaria L Caruso
Feb 3, 2007·BioTechniques·Lanlan ShenJean-Pierre J Issa
Feb 27, 2007·Cell·Peter A Jones, Stephen B Baylin
Mar 27, 2007·Digestive Diseases·E SamantasS K Rigatos
Apr 20, 2007·Journal of Cellular Physiology·Chun-Yu ChoWen-Chun Hung
Oct 20, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lanlan ShenJean-Pierre J Issa
Nov 28, 2007·Clinical Colorectal Cancer·Georg LurjeHeinz-Josef Lenz
Dec 18, 2007·Lancet·UNKNOWN Quasar Collaborative GroupDavid J Kerr
Mar 14, 2008·The New England Journal of Medicine·Manel Esteller
May 20, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Guoren DengYoung S Kim
Sep 9, 2008·Gastroenterology·William M Grady, John M Carethers
Nov 27, 2008·Journal of the National Cancer Institute·Shuji OginoCharles S Fuchs
Jan 7, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel SargentAimery de Gramont
Feb 3, 2009·Nature Cell Biology·Young Mi OhJae Hong Seol
Jun 19, 2009·Nature Reviews. Cancer·Axel WaltherDavid Kerr
Mar 23, 2010·Lancet·David CunninghamNaureen Starling
May 26, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel J SargentSteven Gallinger
Jul 9, 2010·CA: a Cancer Journal for Clinicians·Ahmedin JemalElizabeth Ward
Oct 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carmen J AllegraNorman Wolmark

❮ Previous
Next ❯

Citations

Feb 24, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xiaoyun LiaoShuji Ogino
Jul 4, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yu ImamuraShuji Ogino
Jun 16, 2012·American Journal of Respiratory and Critical Care Medicine·Yan Y SandersJames S Hagood
Mar 28, 2012·Epigenomics·Muriel X G DrahtKim M Smits
Apr 15, 2014·ISRN Gastroenterology·Jiaqiu LiXian Wang
Jan 1, 2014·Cancer Metastasis Reviews·Sarah DerksManon van Engeland
Dec 14, 2011·Cellular and Molecular Life Sciences : CMLS·Sheru Sanbhnani, Foong May Yeong
Sep 8, 2015·Epigenomics·Wenji YanMingzhou Guo
Jul 23, 2013·International Journal of Cancer. Journal International Du Cancer·Lorraine PelosofNilofer S Azad
Feb 25, 2014·Molecular Oncology·Muriel X G DrahtManon van Engeland
Aug 13, 2015·Pharmacogenomics·Maria Anna SmolleArmin Gerger
Mar 23, 2018·Clinical Epigenetics·Muriel X G DrahtKim M Smits
Jun 15, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Arjen H G ClevenManon van Engeland
Dec 7, 2021·Frontiers in Medicine·Iranzu González-BorjaAntonio Viúdez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.